Loading…
Centessa Pharmaceuticals plc is projected to rise to $60.98 by 2027, a +53% move from its current price of $39.77. CNTA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $39.22 | $39.80 | $40.38 | +0.07% |
| May 30 | $39.01 | $39.82 | $40.65 | +0.14% |
| May 31 | $38.86 | $39.85 | $40.87 | +0.20% |
| Jun 1 | $38.74 | $39.88 | $41.05 | +0.27% |
| Jun 2 | $38.63 | $39.91 | $41.22 | +0.34% |
| Jun 3 | $38.54 | $39.93 | $41.38 | +0.41% |
| Jun 4 | $38.45 | $39.96 | $41.52 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.45 | $39.96 | $41.52 | +0.48% |
| Week 2 | $38.03 | $40.15 | $42.39 | +0.96% |
| Week 3 | $37.75 | $40.34 | $43.12 | +1.44% |
| Week 4 | $37.54 | $40.53 | $43.77 | +1.92% |
| Week 5 | $37.38 | $40.73 | $44.38 | +2.41% |
| Week 6 | $37.25 | $40.92 | $44.96 | +2.90% |
| Week 7 | $37.14 | $41.12 | $45.51 | +3.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Centessa Pharmaceuticals plc, CNTA, is a healthcare company focused on orexin-based neuroscience therapies. It currently trades with a price of $39.75 and a market cap of $6.15B, ranking 1195 by size among listed assets. The description highlights ongoing programs including ORX750, ORX142, ORX489, and LockBody across UK and US locations.
A major floor 44.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 0.7% above — clearing it would confirm fresh momentum.
Key CNTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $39.77 | Sell | $39.75 | Buy |
| MA 10 | $39.70 | Buy | $39.71 | Buy |
| MA 20 | $39.64 | Buy | $39.44 | Buy |
| MA 50 | $37.30 | Buy | $36.96 | Buy |
| MA 100 | $31.05 | Buy | $33.14 | Buy |
| MA 200 | $27.15 | Buy | $28.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.18 | Sell |
| Stoch RSI (14) | 17.94 | Buy |
| CCI (20) | 106.63 | Buy |
| Williams %R (14) | -17.39 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | 0.45 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 82.61 | Sell |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 73.00 | Sell |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 39.81 | Sell |
| ADX (14) | 44.79 | Buy |
| ATR (14) | 0.13 | Info |
The current technical setup shows a bullish tone. The RSI(14) sits at 70, indicating strong near-term momentum, with the 50-day simple moving average at $36.80 and the 200-day simple moving average at $26.92 adding support for an uptrend. Nearby support is indicated at $39.42 and resistance at $39.81, while the stock has traded within a 30-day range of $36.12 to $43.74, reflecting compressed volatility relative to the broader market.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.02 | $39.77 | $57.29 | 0% | Neutral | |
| $49.81 | $60.98 | $78.13 | +53% | Bullish | |
| $63.66 | $79.35 | $104.32 | +100% | Bullish | |
| $72.74 | $92.04 | $123.53 | +131% | Bullish | |
| $78.45 | $100.59 | $137.40 | +153% | Bullish | |
| $93.83 | $121.75 | $168.89 | +206% | Bullish | |
| $104.88 | $137.62 | $193.59 | +246% | Bullish | |
| $123.60 | $163.88 | $233.48 | +312% | Bullish | |
| $154.54 | $206.93 | $298.30 | +420% | Bullish | |
| $164.90 | $222.88 | $324.85 | +460% | Bullish | |
| $285.37 | $402.23 | $614.16 | +911% | Bullish | |
| $521.68 | $788.47 | $1,290.16 | +18.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $22.02 | $39.77 | $46.54 | +0.00% |
| June 2026 | $34.72 | $40.50 | $48.16 | +1.83% |
| July 2026 | $36.06 | $42.31 | $50.79 | +4.48% |
| August 2026 | $36.52 | $43.05 | $52.05 | +1.73% |
| September 2026 | $36.20 | $42.82 | $52.09 | -0.52% |
| October 2026 | $37.10 | $44.04 | $53.86 | +2.84% |
| November 2026 | $38.54 | $45.88 | $56.37 | +4.18% |
| December 2026 | $38.88 | $46.42 | $57.29 | +1.17% |
Click any year to see its month-by-month CNTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CNTA is projected to trade between $22.02 and $57.29, averaging $39.77 — a potential gain of 0% from today's $39.77. A consolidation phase looks the most probable path here.
Centessa Pharmaceuticals plc's 2027 outlook centres on $60.98, within a $49.81 to $78.13 range. That is up +53% on the projected 2026 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2028, CNTA could reach as high as $104.32, with a base case around $79.35 and support toward $63.66 — roughly +100% from $39.77. Buyers look set to stay in control over this stretch.
Expect CNTA to range from $72.74 to $123.53 through 2029. The $92.04 average target implies a +131% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The CNTA price prediction for 2030 points to an average of $100.59 (low $78.45, high $137.40) — a potential gain of +153% on today's $39.77. Buyers look set to stay in control over this stretch.
In 2031, CNTA is projected to trade between $93.83 and $168.89, averaging $121.75 — a potential gain of +206% from today's $39.77. That is up +21% on the projected 2030 average. Momentum favours further upside here.
Centessa Pharmaceuticals plc's 2032 outlook centres on $137.62, within a $104.88 to $193.59 range. That is up +13% on the projected 2031 average. That marks a +246% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CNTA could reach as high as $233.48, with a base case around $163.88 and support toward $123.60 — roughly +312% from $39.77. Momentum favours further upside here.
Expect CNTA to range from $154.54 to $298.30 through 2034. The $206.93 average target implies a +420% move from current prices. That is up +26% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CNTA price prediction for 2035 points to an average of $222.88 (low $164.90, high $324.85) — a potential gain of +460% on today's $39.77. Momentum favours further upside here.
In 2040, CNTA is projected to trade between $285.37 and $614.16, averaging $402.23 — a potential gain of +911% from today's $39.77. That is up +80% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Centessa Pharmaceuticals plc's 2050 outlook centres on $788.47, within a $521.68 to $1,290.16 range. That is up +96% on the projected 2040 average. That marks a +18.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CNTA today (≈ 25.144581 CNTA) could be worth
$19,825.87
+$18,825.87 (+1883%) by 2050 · US Dollar
Based on the average projected CNTA price of $788.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNTAwould be worth at today's price.
$1,000 invested in CNTA on May 27, 2025 (≈ 78.308533 CNTA) would be worth
$3,114.33
+$2,114.33 (+211.4%) today · 3.11× · US Dollar
Based on a CNTA entry price of $12.77 vs. today's $39.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.75 | $1,000.5 | +0.1% |
| 1 month ago | $39.51 | $1,006.58 | +0.7% |
| 3 months ago | $26.77 | $1,485.62 | +48.6% |
| 6 months ago | $29.03 | $1,369.96 | +37.0% |
| 1 year ago | $12.77 | $3,114.33 | +211.4% |
| All time (5.0y) ago | $23.58 | $1,686.6 | +68.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNTA forecast.
Our base-case forecast reaches $80.00 around 2029.
Implied market cap at $80.00: $12.38B
Forecasts extend through 2050, with a clear multi-year uptrend. In 2026 the average price is $39.75 with a neutral sentiment and a 0% ROI, followed by a bullish trajectory from 2027 onward as the average price rises to $61.44 in 2027, $79.31 in 2028, and $91.62 in 2029. By 2030 the average is projected at $100.93 with a 153.9% ROI, and by 2035 an average of $221.62 with a 457.5% ROI.
The path continues to 2040, where the average is $400.60 and the ROI is 907.8%, and reaches an average of $782.92 in 2050 with a 1869.6% ROI. Sentiment remains bullish across these years, though these figures are estimates and not guarantees, reflecting potential upside with substantial volatility inherent in growth trajectories.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $78.71, an average of $100.93, and a max of $137.90, with a ROI of 153.9% and a bullish sentiment.
Forecasts show a bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $61.44, 2028 avg $79.31, 2029 avg $91.62, 2030 avg $100.93) and sizable ROIs, but outcomes are estimates and not guaranteed.
Yes. The 2035 forecast lists an average of $221.62 and a max of $323.05, indicating the potential to exceed $150 within that horizon.
For 2050 the min is $517.96, the average is $782.92, and the max is $1,281.17, with a 1869.6% ROI and bullish sentiment.
The current price is $39.75 and the market cap is $6.15B.
Centessa Pharmaceuticals plc Community Discussion
0Share your Centessa Pharmaceuticals plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.